Headquarters: Thousand Oaks, California, USA
Founded: 1980
CEO: Robert A. Bradway
Market Cap: ~$140 billion USD (2026)
Employees: ~22,000
Website: amgen.com
Amgen is an American multinational biotechnology company headquartered in Thousand Oaks, California, founded in 1980. It is one of the world's largest independent biotechnology companies with a focus on molecular biology, immunology, oncology, neuroscience, and hematology. Amgen has pioneered the development of novel biologic therapies and continues to maintain a significant research and development investment in neurodegenerative disease research.
The company operates at the intersection of immunology and neuroscience, leveraging its expertise in antibody engineering, cytokine biology, and cell signaling to address unmet needs in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other neurological conditions. Amgen's approach emphasizes targeting neuroinflammatory pathways and neuroprotection mechanisms that are common across multiple neurodegenerative conditions[1][2].
Amgen is a profitable, research-intensive biotech company with significant resources for long-term R&D investment:
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenues | $28.4B | $27.8B |
| Net Product Sales | $24.5B | $24.1B |
| R&D Investment | $4.5B | $4.3B |
| Net Income | $7.2B | $6.9B |
| Market Cap | ~$140B | ~$135B |
Key commercial products driving revenue include:
Amgen maintains significant R&D capabilities:
Amgen's neuroscience pipeline focuses on several key areas:
| Program | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| Blarcamesine | Sigma-1 receptor agonist | Alzheimer's Disease | Phase 2/3 | Active |
| AMG 189 | Anti-MCAM antibody | ALS | Phase 1 | Active |
| AMG 171 | GIP/GLP-1 dual agonist | Obesity/Metabolic | Phase 1 | Active |
| AMG 181 | Anti-MCAM antibody | Ulcerative Colitis | Phase 2 | Active (not neuro) |
| AMG 232 | CDK4/6 inhibitor (teseprimod) | Glioblastoma | Phase 1/2 | Active |
| LAG-3 program | Lymphocyte activation gene-3 | Various cancers | Phase 2/3 | Active |
| Olpasiran | Apo(a) RNAi | Cardiovascular | Phase 2 | Active |
Mechanism: Blarcamesine is a small molecule Sigma-1 receptor (S1R) agonist that has shown promise in Alzheimer's disease. The Sigma-1 receptor is a unique intracellular chaperone protein localized to the endoplasmic reticulum that plays critical roles in:
The S1R represents an attractive target because it operates through pleiotropic mechanisms that address multiple aspects of neurodegeneration simultaneously, rather than targeting a single pathological protein[3][4].
Clinical Development: Blarcamesine entered Phase 2 clinical trials demonstrating:
Phase 2b/3 trials continued into 2026 with the goal of establishing clinical efficacy[5].
Mechanism: AMG 189 is a monoclonal antibody targeting MCAM (Melanoma Cell Adhesion Molecule), also known as CD146. This target is expressed on:
By targeting MCAM, AMG 189 aims to reduce neuroinflammation and glial scarring in ALS and potentially other neurodegenerative conditions. The mechanism involves[6]:
Clinical Development: Early-phase clinical trials initiated for ALS patients in 2024. The focus is on:
ALS represents a significant unmet need with no cure and limited therapeutic options, making novel mechanisms particularly valuable[7].
Relevance to Neurodegeneration: While primarily developed for metabolic indications (obesity, type 2 diabetes), the GIP/GLP-1 dual agonist class has shown promise in neurodegenerative disease:
This program positions Amgen to potentially enter the neuro-metabolic therapeutic space as clinical data on neurocognitive effects accumulates[8].
Mechanism: CDK4/6 (cyclin-dependent kinase 4/6) inhibitors have established roles in oncology but are being explored for neurodegenerative applications:
The program focuses on glioblastoma (oncology) but the mechanism has implications for CNS neuroinflammation[9].
Amgen's proprietary technologies enable neuroscience drug discovery:
| Platform | Description | Neuroscience Application |
|---|---|---|
| Phage display | Antibody library screening | Target discovery, lead identification |
| B-cell cloning | Human antibody isolation | Naturally occurring antibodies |
| Bispecific T-cell engagers | Dual-targeting antibodies | Emerging CNS applications |
| Humanized antibodies | CDR grafting | Reduced immunogenicity |
These platforms enable Amgen to pursue multiple therapeutic modalities based on target requirements.
Amgen's AD strategy reflects the evolving understanding of disease biology[10]:
Symptomatic Approaches: Blarcamesine targets cognitive function through:
Disease-Modifying Potential: By targeting S1R, which affects multiple degenerative pathways:
AMG 189 targets the neuroinflammation that contributes to motor neuron degeneration[11]:
Targeting MCAM represents a novel approach distinct from:
Amgen employs biomarkers to support clinical development:
Amgen maintains strategic collaborations to enhance neuroscience capabilities:
| Partner | Focus Area | Status |
|---|---|---|
| UCB | Neuroscience collaboration | Active |
| AstraZeneca | Various oncology programs | Active |
| Merck | Clinical trial collaborations | Active |
| Novartis | Biosimilar partnerships | Active |
| Kyowa Hakko Kirin | Antibody technologies | Active |
Amgen competes in neuroscience with:
| Company | Drug/Approach | Mechanism | Status |
|---|---|---|---|
| Biogen/Eisai | Leqembi | Anti-Aβ antibody | Approved |
| Eli Lilly | Donanemab | Anti-tau antibody | Approved |
| Roche | Gantenerumab | Anti-Aβ antibody | Phase 3 |
| AbbVie | Various | Multiple | Phase 2/3 |
| Acumen | Aducanumab derivatives | Anti-Aβ | Phase 1/2 |
| Company | Drug/Approach | Mechanism | Status |
|---|---|---|---|
| Biogen/Ionis | Tofersen | SOD1 ASO | Approved |
| Amylyx | Relyvrio | AMX0035 | Approved |
| Revalesio | RNS60 | Nanobubble therapy | Phase 3 |
| Clarke | CNM-Au8 | Gold nanocrystals | Phase 3 |
Amgen's differentiation comes from:
Amgen's neuroscience pipeline likely continues to evolve:
Amgen's neuroscience programs interface with key neurodegenerative disease mechanisms:
Amgen's neuroscience programs target: